{"id":12370,"date":"2026-11-02T23:22:55","date_gmt":"2026-11-02T20:22:55","guid":{"rendered":"https:\/\/www.ortaakarsu.net\/?ism_drug=ibrutinib"},"modified":"2026-11-02T23:22:55","modified_gmt":"2026-11-02T20:22:55","slug":"ibrutinib","status":"publish","type":"ism_drug","link":"https:\/\/www.ortaakarsu.net\/?ism_drug=ibrutinib","title":{"rendered":"Ibrutinib"},"content":{"rendered":"<p>\u0130brutinib, baz\u0131 B h\u00fccreli kanserlerde kullan\u0131lan bir BTK inhibit\u00f6r\u00fcd\u00fcr. Kanama, ciddi enfeksiyon ve ritim bozuklu\u011fu riski nedeniyle re\u00e7etesiz ila\u00e7lar dahil t\u00fcm tedaviler birlikte de\u011ferlendirilir.<\/p>\n<details>\n<summary>Kaynaklar ve belge kapsam\u0131<\/summary>\n<ul>\n<li><a href=\"https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/imbruvica-epar-product-information_en.pdf\" rel=\"nofollow noopener\" target=\"_blank\">Imbruvica \u2014 EMA product information, Annex I SmPC<\/a><\/li>\n<li><a href=\"https:\/\/ilac101.com\/pdf_\/kub\/ilac101_kub_adfa96f02df811a.pdf\" rel=\"nofollow noopener\" target=\"_blank\">IMBRUVICA 140 mg sert kaps\u00fcl K\u00dcB<\/a><\/li>\n<li><a href=\"https:\/\/www.fda.gov\/drugs\/drug-interactions-labeling\/healthcare-professionals-fdas-examples-drugs-interact-cyp-enzymes-and-transporter-systems\" rel=\"nofollow noopener\" target=\"_blank\">FDA examples of drugs that interact with CYP enzymes and transporter systems<\/a><\/li>\n<li><a href=\"https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xtandi-epar-product-information_en.pdf\" rel=\"nofollow noopener\" target=\"_blank\">Xtandi \u2014 EMA product information, Annex I SmPC<\/a><\/li>\n<li><a href=\"https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/erleada-epar-product-information_en.pdf\" rel=\"nofollow noopener\" target=\"_blank\">Erleada \u2014 EMA product information, Annex I SmPC<\/a><\/li>\n<li><a href=\"https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/venclyxto-epar-product-information_en.pdf\" rel=\"nofollow noopener\" target=\"_blank\">Venclyxto \u2014 EMA product information, Annex I SmPC<\/a><\/li>\n<li><a href=\"https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kisqali-epar-product-information_en.pdf\" rel=\"nofollow noopener\" target=\"_blank\">Kisqali \u2014 EMA product information, Annex I SmPC<\/a><\/li>\n<li><a href=\"https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=19599\" rel=\"nofollow noopener\" target=\"_blank\">PAXLOVID US prescribing information<\/a> \u2014 Revised 02\/2026<\/li>\n<\/ul>\n<\/details>\n","protected":false},"excerpt":{"rendered":"<p>\u0130brutinib, baz\u0131 B h\u00fccreli kanserlerde kullan\u0131lan bir BTK inhibit\u00f6r\u00fcd\u00fcr. Kanama,  [&#8230;]<\/p>\n","protected":false},"featured_media":0,"template":"","ism_etken_madde":[1540],"class_list":["post-12370","ism_drug","type-ism_drug","status-publish","hentry","ism_etken_madde-ibrutinib"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/ism_drug\/12370","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/ism_drug"}],"about":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/types\/ism_drug"}],"version-history":[{"count":0,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/ism_drug\/12370\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=12370"}],"wp:term":[{"taxonomy":"ism_etken_madde","embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Fism_etken_madde&post=12370"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}